245 related articles for article (PubMed ID: 33356554)
1. Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition.
Matissek SJ; Han W; Karbalivand M; Sayed M; Reilly BM; Mallat S; Ghazal SM; Munshi M; Yang G; Treon SP; Walker SR; Elsawa SF
Epigenomics; 2021 Jan; 13(2):129-144. PubMed ID: 33356554
[No Abstract] [Full Text] [Related]
2. Co-Binding of JQ1 and Venetoclax Exhibited Synergetic Inhibitory Effect for Cancer Therapy; Potential Line of Treatment for the Waldenström Macroglobulinemia Lymphoma.
Elamin G; Aljoundi A; Soliman MES
Chem Biodivers; 2022 Jul; 19(7):e202100845. PubMed ID: 35610180
[TBL] [Abstract][Full Text] [Related]
3. Waldenstrom macroglobulinemia cells devoid of BTK
Paulus A; Akhtar S; Yousaf H; Manna A; Paulus SM; Bashir Y; Caulfield TR; Kuranz-Blake M; Chitta K; Wang X; Asmann Y; Hudec R; Springer W; Ailawadhi S; Chanan-Khan A
Blood Cancer J; 2017 May; 7(5):e565. PubMed ID: 28548645
[TBL] [Abstract][Full Text] [Related]
4. Venetoclax in Previously Treated Waldenström Macroglobulinemia.
Castillo JJ; Allan JN; Siddiqi T; Advani RH; Meid K; Leventoff C; White TP; Flynn CA; Sarosiek S; Branagan AR; Demos MG; Guerrera ML; Kofides A; Liu X; Munshi M; Tsakmaklis N; Xu L; Yang G; Patterson CJ; Hunter ZR; Davids MS; Furman RR; Treon SP
J Clin Oncol; 2022 Jan; 40(1):63-71. PubMed ID: 34793256
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia.
Castillo JJ; Branagan AR; Sermer D; Flynn CA; Meid K; Little M; Stockman K; White T; Canning A; Guerrera ML; Kofides A; Liu S; Liu X; Richardson K; Tsakmaklis N; Patterson CJ; Hunter ZR; Treon SP; Sarosiek S
Blood; 2024 Feb; 143(7):582-591. PubMed ID: 37971194
[TBL] [Abstract][Full Text] [Related]
6. Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.
Castillo JJ; Hunter ZR; Yang G; Treon SP
Expert Rev Hematol; 2017 Aug; 10(8):739-744. PubMed ID: 28617062
[TBL] [Abstract][Full Text] [Related]
7. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
Cyrenne BM; Lewis JM; Weed JG; Carlson KR; Mirza FN; Foss FM; Girardi M
Blood; 2017 Nov; 130(19):2073-2083. PubMed ID: 28972015
[TBL] [Abstract][Full Text] [Related]
8. What is new in the treatment of Waldenstrom macroglobulinemia?
Castillo JJ; Treon SP
Leukemia; 2019 Nov; 33(11):2555-2562. PubMed ID: 31591468
[TBL] [Abstract][Full Text] [Related]
9. Multi-catalytic Sites Inhibition of Bcl2 Induces Expanding of Hydrophobic Groove: A New Avenue Towards Waldenström Macroglobulinemia Therapy.
Elamin G; Aljoundi A; Soliman MES
Protein J; 2022 Apr; 41(2):201-215. PubMed ID: 35237907
[TBL] [Abstract][Full Text] [Related]
10. Targeting epigenetic mechanisms to overcome venetoclax resistance.
Prado G; Kaestner CL; Licht JD; Bennett RL
Biochim Biophys Acta Mol Cell Res; 2021 Jul; 1868(8):119047. PubMed ID: 33945824
[TBL] [Abstract][Full Text] [Related]
11. microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia.
Roccaro AM; Sacco A; Jia X; Azab AK; Maiso P; Ngo HT; Azab F; Runnels J; Quang P; Ghobrial IM
Blood; 2010 Sep; 116(9):1506-14. PubMed ID: 20519629
[TBL] [Abstract][Full Text] [Related]
12. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells.
Cao Y; Yang G; Hunter ZR; Liu X; Xu L; Chen J; Tsakmaklis N; Hatjiharissi E; Kanan S; Davids MS; Castillo JJ; Treon SP
Br J Haematol; 2015 Jul; 170(1):134-8. PubMed ID: 25582069
[No Abstract] [Full Text] [Related]
13. Ibrutinib for the treatment of Waldenström macroglobulinemia.
Chakraborty R; Kapoor P; Ansell SM; Gertz MA
Expert Rev Hematol; 2015 Oct; 8(5):569-79. PubMed ID: 26138997
[TBL] [Abstract][Full Text] [Related]
14. How to Sequence Therapies in Waldenström Macroglobulinemia.
Sarosiek S; Treon SP; Castillo JJ
Curr Treat Options Oncol; 2021 Aug; 22(10):92. PubMed ID: 34426943
[TBL] [Abstract][Full Text] [Related]
15. Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Chakraborty R; Kapoor P; Ansell SM; Gertz MA
Expert Rev Anticancer Ther; 2015; 15(10):1143-56. PubMed ID: 26196236
[TBL] [Abstract][Full Text] [Related]
16. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia.
Ghobrial IM; Campigotto F; Murphy TJ; Boswell EN; Banwait R; Azab F; Chuma S; Kunsman J; Donovan A; Masood F; Warren D; Rodig S; Anderson KC; Richardson PG; Weller E; Matous J
Blood; 2013 Feb; 121(8):1296-303. PubMed ID: 23287861
[TBL] [Abstract][Full Text] [Related]
17. Management of Waldenström macroglobulinemia in 2020.
Castillo JJ; Treon SP
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):372-379. PubMed ID: 33275726
[TBL] [Abstract][Full Text] [Related]
18. Emerging drugs for the treatment of Waldenström macroglobulinemia.
Despina F; Meletios Athanasios D; Efstathios K
Expert Opin Emerg Drugs; 2020 Dec; 25(4):433-444. PubMed ID: 32955949
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia.
Sun JY; Xu L; Tseng H; Ciccarelli B; Fulciniti M; Hunter ZR; Maghsoudi K; Hatjiharissi E; Zhou Y; Yang G; Zhu B; Liu X; Gong P; Ioakimidis L; Sheehy P; Patterson CJ; Munshi NC; O'Connor OA; Treon SP
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):152-6. PubMed ID: 21454220
[TBL] [Abstract][Full Text] [Related]
20. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.
Yang G; Buhrlage SJ; Tan L; Liu X; Chen J; Xu L; Tsakmaklis N; Chen JG; Patterson CJ; Brown JR; Castillo JJ; Zhang W; Zhang X; Liu S; Cohen P; Hunter ZR; Gray N; Treon SP
Blood; 2016 Jun; 127(25):3237-52. PubMed ID: 27143257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
